GE HealthCare Technologies Inc. (NASDAQ:GEHC) Stake Lessened by WR Wealth Planners LLC

WR Wealth Planners LLC lowered its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 10.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 9,124 shares of the company’s stock after selling 1,064 shares during the period. WR Wealth Planners LLC’s holdings in GE HealthCare Technologies were worth $713,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Mesirow Financial Investment Management Inc. lifted its holdings in shares of GE HealthCare Technologies by 39.6% in the third quarter. Mesirow Financial Investment Management Inc. now owns 4,084 shares of the company’s stock valued at $383,000 after purchasing an additional 1,159 shares in the last quarter. Cathy Pareto & Associates Inc. purchased a new stake in shares of GE HealthCare Technologies in the fourth quarter valued at $670,000. LMR Partners LLP purchased a new stake in shares of GE HealthCare Technologies in the third quarter valued at $7,387,000. Principal Financial Group Inc. lifted its holdings in shares of GE HealthCare Technologies by 1.9% in the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock valued at $94,780,000 after purchasing an additional 19,010 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in shares of GE HealthCare Technologies in the third quarter valued at $1,396,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

GEHC has been the subject of several recent research reports. Wells Fargo & Company increased their price objective on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their price objective for the stock from $95.00 to $103.00 in a report on Wednesday, January 8th. Finally, Citigroup increased their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $97.67.

GE HealthCare Technologies Trading Down 2.3 %

GE HealthCare Technologies stock opened at $87.35 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The company has a market capitalization of $39.94 billion, a price-to-earnings ratio of 20.17, a PEG ratio of 3.19 and a beta of 1.15. GE HealthCare Technologies Inc. has a one year low of $74.51 and a one year high of $94.80. The company’s fifty day moving average price is $86.17 and its two-hundred day moving average price is $86.10.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its earnings results on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. On average, analysts forecast that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.